Thank you, Alex, for a review of outcome data for one of the newest diabetes medications: canaglifozin (Invokana®).  Canaglifozin is a SGLT2 inhibitor, which decreases reabsorption of glucose in the renal tubules.

Clinical Question: Among patients with DM2 at high risk for CV events, does daily canagliflozin reduce CV mortality, nonfatal MI, or nonfatal strokes when compared to placebo?

The short answer is there are likely cardiovascular benefits of this medication class, unseen in other oral diabetes medications since studies showed cardiovascular benefits with metformin.  However, there are potential side effects including increased risk of amputations and fractures.  Review the presentation and read the article to find out more!